Toggle navigation
Home
Search
Services
Blog
Contact
About
Development of Tumor Vaccines Using Gpi-Linked Molecules
Segal, Andrew H.
Genitrix, LLC, Cambridge, MA, United States
Search 10 grants from Andrew Segal
Search grants from Genitrix, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The Self Regulation Model in BRCA 1/2 Genetic Counseling
Cancer Center Support Grant
Core - Pathology
Hypothalamic Pituitary Adrenal Axis and Neurobehavioral Effects of Cocaine
Effects of Menhaden Oil on Carcinogenesis.
Recently added grants:
Developing an Implementation Strategy to Improve Peri-procedural Anticoagulation Management for Patients with Atrial Fibrillation
Linking State Medicaid and Congenital Heart Surgical Registry Data: Building Capacity to Assess Disparities in Longitudinal Outcomes and Value for Children with Congenital Heart Disease
cAMP Compartmentation in Cardiac Myocytes
Simulating Cardiac Surgery for Children with Severe Congenital Heart Disease
Molecular Mechanisms of Electrical Synapse Formation in Vivo
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA074665-01A1
Application #
2422939
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Program Officer
Reynolds, Craig W
Project Start
1997-09-30
Project End
1999-06-30
Budget Start
1997-09-30
Budget End
1999-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Genitrix, LLC
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Related projects
NIH 1999
R43 CA
Development of Tumor Vaccines Using Gpi Linked Molecules
Segal, Andrew H. / Genitrix, LLC
NIH 1997
R43 CA
Development of Tumor Vaccines Using Gpi-Linked Molecules
Segal, Andrew H. / Genitrix, LLC
Comments
Be the first to comment on Andrew Segal's grant